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Abstract 41 
The tall cell variant of papillary thyroid carcinoma (PTC) has an unfavorable prognosis. The 42 
diagnostic criteria remain inconsistent and the role of a minor tall cell (TC) component is unclear. 43 
Molecular diagnostic markers are not available; however, there are two potential candidates: BRAF 44 
V600E and TERT promoter mutations. Using a novel approach, we enriched a collective with PTC 45 
harboring an adverse outcome, overcoming the limited statistical power of most studies. This 46 
enabled us to review 125 PTC patients, 57 of them with an adverse outcome. The proportion of TC 47 
that constitute a poor prognosis was assessed. All tumors underwent sequencing for TERT promoter 48 
and BRAF V600E mutational status and were stained with an antibody detecting the BRAF V600E 49 
mutation. A 10% cut off for TC was significantly associated with advanced tumor stage and lymph 50 
node metastasis. Multivariate analysis showed that tall cells above 10% were the only significant 51 
factor for overall, tumor-specific and relapse-free survival. 7% of cases had a TERT promoter mutation 52 
while 61% demonstrated a BRAF mutation. The presence of TC was significantly associated with 53 
TERT promoter and BRAF mutations. TERT predicted highly significant tumor relapse (p<0.001). PTC 54 
comprising of at least 10% TC are associated with an adverse clinical outcome and should be reported 55 
accordingly. BRAF did not influence patient outcome. Nevertheless, a positive status should encourage 56 
the search for tall cells. TERT promoter mutations are a strong predictor of tumor relapse but their role 57 
as a surrogate marker for TC is limited. 58 
 59 
 60 
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Introduction 62 
Thyroid carcinoma is classified into five different morphological groups: papillary, follicular, 63 
medullary, poorly differentiated and anaplastic/undifferentiated(DeLellis, et al. 2004). These 64 
endocrine cancers account for approximately 1% of all malignancies(Schlumberger 1998). Papillary 65 
thyroid carcinomas (PTC) are among the most curable cancers and total thyroidectomy followed by 66 
adjuvant radioiodine administration cures almost all patients. Patient prognosis depends upon age, 67 
gender, tumor size or extrathyroidal extension, the latter two of which are reflected in the UICC TNM 68 
staging system(Sobin S. 2009). On a morphologic basis, PTC are subdivided into different subtypes as 69 
recognized by the WHO-classification(DeLellis et al. 2004). Nevertheless, this sub-classification has 70 
little clinical significance since the different subtypes do not add independent prognostic value. As a 71 
result the vast majority of PTC is not sub-classified routinely. A grading system of PTC has been 72 
proposed that included nuclear atypia, tumor necrosis and vascular invasion as signs for poorly 73 
differentiated PTC(Akslen and LiVolsi 2000). However most of these tumors would nowadays 74 
probably be classified as poorly differentiated thyroid carcinomas(Volante, et al. 2007). Different 75 
staging systems for PTC have been introduced. Unfortunately, they are very complex and as a 76 
consequence, they are not used on a daily basis in most institutions. In fact, it is very difficult to 77 
predict which patients will suffer from recurrent disease or death from PTC and which will be cured 78 
by the combination of surgery and radioiodine treatment(Nikiforov 2012).  79 
Among the different PTC subtypes, the tall cell variant (TCV) is known to have a more 80 
aggressive clinical behavior(LiVolsi 2010). However, the morphological criteria for the diagnosis of 81 
this entity is not clear defined by the WHO (“The TCV is composed predominantly of cells whose 82 
heights are at least three times their widths.”) and especially the percentage of tall cells (TC) needed in 83 
a given tumor is defined variably in the literature(DeLellis et al. 2004; Ostrowski and Merino 1996).  84 
The oncogenic BRAF V600E mutation occurs in about 40-45% of PTC(Nikiforov 2012). It 85 
activates the mitogen-activated protein kinase signaling pathway (MAPK) in human cancer and has 86 
been shown to correlate with aggressive features in PTC including extrathyroidal extension, lymph 87 
node metastasis and the TCV(Kim, et al. 2012; Koperek, et al. 2012; Li, et al. 2012; Xing, et al. 2013). 88 
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An increasing number of studies including meta-analyses were able to demonstrate an association 89 
between BRAF status and aggressive tumor behavior(Elisei, et al. 2012; Kim et al. 2012; Li et al. 90 
2012; Xing et al. 2013). Other studies, however, could not confirm this data, resulting in uncertainty of 91 
the value of BRAF in PTC (Barbaro, et al. 2014; Cheng, et al. 2011; Eloy, et al. 2011; Ito, et al. 2009; 92 
Koperek et al. 2012; Sancisi, et al. 2012). One reason for this could be the fact that an adverse patient 93 
outcome with multiple tumor relapses and eventually death due to PTC is a rare event. As a matter of 94 
fact, only about 5% of PTC will have an adverse outcome in consecutive clinicopathological series, 95 
leading to very small groups of high-risk tumors with limited statistical power in different 96 
studies(Handkiewicz-Junak, et al. 2010).  97 
Reactivation of the telomerase reverse transcriptase (TERT) gene which encodes for the 98 
catalytic subunit of telomerase is implicated in tumorigenesis and cell immortalization. The two 99 
promoter mutations C228T and C250T were recently reported in human melanomas and other human 100 
cancer types including thyroid(Huang, et al. 2013; Liu, et al. 2013a; Vinagre, et al. 2013). They are a 101 
novel mechanism in tumor biology, generating de novo consensus binding motifs for ETS (E-twenty-102 
six) transcription factors, increasing the activity of the TERT promoter with potential clinical 103 
applications and prognostic value(Huang et al. 2013; Landa, et al. 2013; Liu, et al. 2013b). 104 
The purpose of this study was to analyze the prevalence, histomorphology and follow-up data 105 
of a cohort of PTC patients enriched for patients with known adverse clinical outcome (ACO) based 106 
on a population of 1.3 million inhabitants over a 16 year period and to determine the threshold of TC 107 
within a given PTC that could impact patient outcome. Further, we sequenced BRAF and TERT 108 
promoter mutations in all tumors and evaluated whether they may serve as surrogate markers for TCV 109 
and an ACO. 110 
 111 
Material and Methods 112 
Since radioiodine treatment is the standard therapy for patients suffering from recurrent 113 
thyroid cancer, virtually all such patients are seen in the department of nuclear medicine. Three such 114 
departments (University Hospital Zürich, City Hospital Triemli, and Cantonal Hospital Winterthur) 115 
serve the 1.3 million inhabitants in the canton of Zürich(Statistics 2011). Fifty-seven patients were 116 
Page 5 of 26
Dettmer et al. Page 6 
 
 
identified in these departments who had thyroid surgery between 1990 and 2006 and had an ACO. 117 
ACO was defined as more than one tumor recurrence or tumor related death. Sixty-eight age-, stage- 118 
and gender-matched patients (without recurrence) treated for PTC at the University Hospital Zürich 119 
were used as the control group (CG; table 1). Tumors with a size of less than 1 cm were excluded from 120 
this study since these microcarcinomas show a very indolent clinical course(Baloch and LiVolsi 2006) 121 
and the significance of TC in this setting is beyond the scope of this study. This approach significantly 122 
enhanced the number of patients with an ACO. Twenty one of the patients had lymph node metastases 123 
whereas 104 patients were node negative. 124 
Archival pathology specimens of the thyroid tumors were reevaluated according to the WHO 125 
classification by three pathologists who were blinded to the clinicopathological data (M.D., A.S., A.P.) 126 
and a consensus diagnosis was rendered(DeLellis et al. 2004). The tumor stage was reclassified based 127 
on the 7th TNM classification(Sobin S. 2009). TC were defined as cells being more than three times as 128 
high as wide, often with an eosinophilic cytoplasm(Nikiforov 2012). A few examples and pitfalls are 129 
shown in figure 1. Although the so-called “tram-track” pattern, especially, at low power is a very 130 
helpful feature, not all areas showing this growth pattern are TC. Also areas exhibiting a classic PTC 131 
growth pattern can be comprised of true TC, thus making it mandatory for the pathologist to examine 132 
all tumors at high magnification. Nuclear stratification, intranuclear inclusions as well as characteristic 133 
coffee bean infoldings of the nuclear membrane were frequently seen(Nikiforov 2012). 134 
The percentage of TC was recorded semiquantitatively in each tumor in 10% increment steps, 135 
ranging from 0-100%, the lowest recorded amount of TC in a given tumor was therefore 10%. All 136 
available slides were assessed in each tumor (6.1±4.5 slides per case in the CG and 5.0±4.5 slides in 137 
the ACO group). Tumors which had anaplastic or poorly differentiated areas, as defined by the Turin 138 
criteria were excluded from the study(Volante et al. 2007), and were reported elsewhere (Dettmer, et 139 
al. 2011; Dettmer, et al. 2012).  140 
DNA was extracted using the DNeasy Blood and Tissue kit and all samples underwent BRAF 141 
pyrosequencing mutation analysis on the PyroMark Q24 System according to the manufacturer’s 142 
instructions (QIAGEN, Hilden, Germany). The primers had the following sequence: forward: 5’-143 
TGAAGACCTCACAGTAAAAATAGG-3’; reverse: 5’-TCCAGACAACTGTTCAAACTGAT-3’; 144 
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sequencing primer: 5’-TGATTTTGGTCTAGCTACA-3’. An allelic fraction of ≥10% of mutant 145 
alleles was defined as positive for the mutation. 146 
A tissue microarray (TMA) has been constructed and stained with the BRAF V600E mutation 147 
specific antibody as previously described (Boos, et al. 2013; Koperek et al. 2012). A tumor was 148 
considered positive when a distinct, homogenous immunoreaction was seen in the cytoplasm of all 149 
cancer cells. Immunohistochemistry and molecular analysis were performed on the same tissue block.  150 
TERT promoter mutations were assessed by PCR followed by Sanger Sequencing as described 151 
(Liu et al. 2013a).  152 
The sample distribution was analyzed using the Kolmogorov-Smirnov test. Chi-square, 153 
Kendall’s tau_b, Kruskal-Wallis, Kaplan-Meier and COX regression were performed using SPSS 154 
statistical software version 21.0 (SPSS, Chicago, IL). A P value of <0.05 was considered statistically 155 
significant. The study was approved by the Cantonal Research Ethics Board Zürich (STV 28-2006).  156 
 157 
Results 158 
Fifty-seven PTC patients with ACO and sixty-eight PTC patients in the CG were analyzed. 159 
The characteristics of the study population are summarized in table 1 and 2. The mean±st.dev. for the 160 
different follow up times in months were: OS (overall survival): 81.97±48.42; TSS (tumor specific 161 
survival): 81.97±48.42; RFS (relapse free survival): 51.78±50.97; CG 81.88±48.5; ACO 81.5±49.5. 162 
There were 68 classic PTC, 47 follicular variants of PTC (FVPTC) and 10 PTC of a special subtype (3 163 
diffuse sclerosing, 2 columnar cell, 2 solid, 2 warthin-like and one oncocytic variant). Seventy-seven 164 
PTC did not display any detectable TCs, 27 PTC showed more than 10% but less than 50% TC and 21 165 
tumors had ≥50% of tumor composed of TC. The distribution of TC and important clinical endpoints 166 
OS, TSS and RFS are summarized in table 2 and table suppl.1.  167 
The tumors comprising of 10- 50% TC showed the presence of TC predominantly at the 168 
invasive front, whereas tumors harboring ≥50% TC showed presence of tall cells in the center of the 169 
tumor as well.  170 
Tall cells: The presence of TC showed significant correlation with patient survival, relapse 171 
and tumor stage. Clinicopathological data for the tumors were also correlated with the different 172 
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thresholds for TC presence in the tumors and ROC curves were calculated to assess the best cut-off 173 
(fig suppl.1; table suppl.2). TC >10% correlated with lymph node metastasis (p<0.001) but not with 174 
organ metastases (p<0.223). TC >50% did not correlate with lymph node metastasis (p<0.141) nor 175 
with organ metastasis (p<0.601). 176 
Kaplan-Meier survival analysis showed significant reduction in OS, TSS and RFS for tumors 177 
having more than 10% TC (each: Log-Rank p<0.001). To further determine what proportion of ≥10% 178 
TC impacts patient prognosis, we subcategorised this group into two groups, namely 10-50% and ≥ 179 
50% TC area. There were no significant differences between the two groups with regards to OS, TSS 180 
and RFS, but in the group with 10% to 50% TC there was a tendency for less aggressive behaviour as 181 
compared to the group with  ≥ 50% TC area (figure 2).  182 
Multivariate Cox regression analysis was performed using patient age, gender, tumor stage 183 
and TC tumor area (<10% vs. ≥10%) for OS, RFS and TSS. For RFS, TC ≥ 10% was the only 184 
parameter that was significant (p<0.0001, Exp(B)=3.6). For OS, the factors that were significant were 185 
age (p<0.010, Exp(B)=6.3) and TC ≥ 10% (p<0.001, Exp(B)=12.9). The analysis could not be 186 
performed for TSS, since no patient in the TC<10% group died. However when the analysis for TSS 187 
was performed using the threshold of TC ≥ 50%, it was significant (p<0.008, Exp(B)=9.3). The 188 
Kruskal-Wallis test revealed a significant association between the number of relapses and the 189 
percentage of TC found in a given tumor (p<0.001; table suppl.3). 190 
BRAF: Pyrosequencing analysis detected BRAF V600E in 72 (61%) PTC cases whereas 46 191 
tumors (39%) were negative. All the mutations were V600E, other BRAF mutations were not detected. 192 
The sensitivity was higher as compared to the mutation specific antibody which detected the mutation 193 
in 63 (50.4%) cases and which was negative in the other 62 (49.6%) patients. The allelic fraction of 194 
BRAF (29.4±13.5, range 10 to 46) mutation did not correlate with patient outcome. Pyrosequencing 195 
was more sensitive in nine discrepant cases and detected the BRAF mutation while the antibody was 196 
negative. Two of these cases had a subsequent lymph node metastasis, which was then positive for 197 
BRAF by the antibody. Only two tumors showing a positive IHC for V600E were negative by 198 
Pyrosequencing. In summary, there was an excellent highly significant correlation between both 199 
detection methods (p<0.001, r=0.600, table suppl.2). 200 
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BRAF status was not associated with patient outcome in the Kaplan Meier analysis or the Cox 201 
regression multivariate analysis (figure 3). There were no associations of BRAF mutations with lymph 202 
node or organ metastases.  203 
Tall cells and BRAF: Sixteen out of 21 patients (76%) had the BRAF mutation when applying 204 
the 50% cutoff for the TCV. This went up to 79% (38 out of 48 patients) when applying the 10% 205 
cutoff to be required to allow the TCV diagnosis. The amount of TC within a given tumor was 206 
significantly associated with the BRAF status (p<0.002, table 3 and table suppl.1).  207 
The allelic fraction as determined by pyrosequencing was influenced by the amount of TC 208 
within a tumor (p<0.034, r=0.156; Kendall’s tau_b). There was no significant association between 209 
BRAF status and an ACO on univariate or multivariate analysis when we analyzed only the TC 210 
tumors, neither for the 10% nor for the 50% cut-off (table 1, table suppl.2, table suppl.3).  211 
Tall cells, BRAF and TERT: TERT promoter mutations were detected in total 8 tumors 212 
(7.3%). The C250T mutation was found in three tumors, the C228T mutation in five. Six patients with 213 
TERT promoter mutations were also BRAF mutated while two were not (p<0.49). TC morphology 214 
correlated significantly with this mutation (p<0.0001, r=0.308) - six of these tumors had a TC 215 
morphology in ≥ 50% whereas one had 30% TC and one had none. All eight patients with the TERT 216 
promoter mutation had a tumor relapse (p<0.001). Tumors that were TERT promoter mutated and 217 
BRAF mutated behaved significantly worse than BRAF mutated tumors only (Log-Rank p<0.019; 218 
table 1 and table suppl.2). 219 
TERT promoter mutations together with pT stage remained an independent predictor of tumor 220 
relapse in a multivariate analysis (TERT promoter mutation: p<0.005; Exp(b)=3.18; pT stage: 221 
p<0.019; Exp(b)=1.58). However, when TC were included in the analysis, they remained the single 222 
independent predictor of RFS (p<0.0001; Exp(b)=3.04) while the other two factors dropped out (table 223 
suppl.3).  224 
The numbers of some parameters do not add up to the total number of patients included in the 225 
study due to dropouts in DNA quality and consecutive failure of mutational testing or due to dropout 226 
of cases on the tissue microarray. 227 
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 228 
Discussion 229 
In this study, we analyzed a large cohort of PTC and TCV with an ACO, delineated the 230 
proportion of TC that is needed to determine patient outcome and assessed the role of BRAF and TERT 231 
promoter mutations in this setting. In our hands a 10% cut-off of TC defines a detrimental prognosis. 232 
BRAF mutation status does not correlate with adverse outcome, but is more frequent in TCV than in 233 
classical PTC. TERT mutations are rare, but associated with a very aggressive course. 234 
Previous clinico-pathological studies on TCV PTC analyzed small groups of tumors with 235 
ACO thereby limiting their statistical power(LiVolsi 2010; Ostrowski and Merino 1996). In our study 236 
this number of patients with ACO was increased to a relatively large sample size via identification of 237 
patients in the departments of nuclear medicine. This approach increased the statistical power in 238 
determining a cut-off of TC leading to poor prognosis. This patient selection is on the other hand also 239 
a limitation of the study since it does not reflect the normal patient population. We can therefore not 240 
exclude that we overestimated the effect of TC in tumors with an ACO and that TC are much more 241 
frequently encountered in a consecutive series of patients where they do not account for an ACO. 242 
However, in our age, stage and gender matched cohort, this was not the case. 243 
The TCV of PTC is a distinct entity of thyroid tumors that is associated with an unfavorable 244 
patient outcome. The threshold of proportion of TC in a given carcinoma to allow for the diagnosis of 245 
TC-variant is poorly defined and differs in the literature from no information at all to 10% up to 246 
75%(Akslen and LiVolsi 2000; DeLellis et al. 2004; LiVolsi 2010; Ostrowski and Merino 1996; 247 
Sobrinho-Simoes, et al. 1989). Our results confirm that PTC comprising more than 50% TC have an 248 
ACO. While this result was expected, it settles the finding in a robust study population. Survival 249 
analysis showed that there was a clear difference between the TC and non-TC PTC using this 50% 250 
cut-off. However, the results were more interesting when a cut-off at 10% was introduced, since the 251 
influence of a minor TC component is unclear and controversial (LiVolsi 2010; Nikiforov 2012). To 252 
exclude the possibility, that PTC comprising of TC ≥50% group skewed the analysis and that TC 253 
component 10-50% did not severely affect patient outcome, we separated the tumors into three groups, 254 
<10% TC, 10-50% TC, and ≥50% TC. The Kaplan-Meier analysis revealed that presence of at least 255 
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10% of TC in a PTC significantly impacted the patient outcome for OS, TSS and RFS. Moreover, 256 
TC≥10% is the only significant factor in a multivariate analysis, which included age, gender and 257 
tumor stage, for ACO.  258 
It has already been proposed by Sobrinho and others that it is important for pathologists to 259 
report the number of TC seen in a given tumor, few as they may be(LiVolsi 2010; Sobrinho-Simoes et 260 
al. 1989). Two studies suggested that a minor TC component may determine patient outcome but they 261 
were not able to confirm this in a univariate respectively multivariate analysis(Beninato, et al. 2013; 262 
Ganly, et al. 2013). The first study did a review on cases that had been diagnosed as TCV or PTC with 263 
a minor TC component(Beninato et al. 2013). With such an approach, we would have missed most of 264 
the TCV in our study. In fact, only three PTC consisting exclusively of TC were diagnosed as TCV in 265 
the original pathology report. All remaining PTC were originally diagnosed as either classical PTC or 266 
FVPTC, even when a threshold of 50% was applied. These underdiagnoses could be due to their rarity 267 
and lack of awareness on the part of the surgical pathologists on the one hand or due to the ambiguous 268 
definition of the condition on the other. The second study defined TC as cells with their height twice 269 
their width and therefore included tumors as TCV, which would not be included as TCV in the present 270 
work. Our results indicate that the strict application of the 2004 WHO definition of TC with cells 271 
being thrice their width stratifies patients better(DeLellis et al. 2004). This study also had only few 272 
patients with adverse events and due to those reasons was probably therefore not significant in the 273 
multivariate analysis(Ganly et al. 2013).  274 
From our study, it is evident that presence of TC component of 10-50% significantly and 275 
independently affects patient prognosis and that there is no statistical difference between the group 276 
with a 10-50% TC and ≥ 50% TC component. The PTC with 10% to 50% of TC would be regarded as 277 
conventional PTC or as PTC with TC features by most authors(Ghossein and Livolsi 2008; LiVolsi 278 
2010). At this point, it is important to specify that we examined approximately 6 tumor blocks per 279 
patient and that examining only one block per tumor would have lowered the rate of detection of TCV 280 
by 11%, using the 10% cut-off. To our knowledge, no image analysis tool is available that would be 281 
able to identify TC within a PTC and quantify their amount in a given tumor.  282 
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The Kaplan-Meier survival analysis in our study suggests that there might be a difference 283 
between the tumors harboring a 10-50% TC versus a ≥ 50% TC component, with the former showing 284 
a tendency for less aggressive behavior. We propose two potential explanations for this finding. 285 
Firstly, there could be a limitation in morphological detection of TC areas in the sub 10% range which 286 
can lead to these tumors being categorized in the 10% to 50% TC group, thereby accounting for the 287 
intermediate results in the Kaplan-Meier analysis. This also implies that the greater the TC component 288 
that was identified, the higher the possibility that this tumor was truly a TC variant of PTC. The 289 
second explanation for this finding is that there could be a gradual increase of TC leading to a 290 
gradually increased aggressiveness. Another argument for the second explanation is the comparison of 291 
TCV to other solid carcinomas. Different subclones in tumors play an important role in the formation 292 
of tumor progression and metastasis (Yachida, et al. 2010). Such more aggressive subclones could 293 
gradually replace the less aggressive clones. A potential driver mutation for TCV PTC might be the 294 
BRAF V600E mutation. Indeed, the present work confirms the fact that BRAF mutations are more 295 
frequently observed in TCV as compared to PTC(Nikiforova, et al. 2003). Further, it was 296 
demonstrated that PTC showing BRAF mutations have a higher frequency of extrathyroidal extension 297 
and nodal metastases than those that are negative for this mutation(Nikiforova et al. 2003).  298 
While our study was not designed to analyze genetic intratumoral heterogeneity, we saw 11 of 299 
125 tumors with different BRAF mutation results in 2 regions and the immunohistochemical BRAF 300 
V600E detection was heterogeneous in two cases while the allelic fraction by pyrosequencing was 301 
above 30% in both cases. These findings support the fact that BRAF tumor heterogeneity occurs in 302 
PTC(Guerra, et al. 2012b) but its prognostic role is unclear, since the allelic fraction did not correlate 303 
with patient outcome which is in contrast to previous findings(Guerra, et al. 2012a). In fact, analyzing 304 
the whole group of PTC we did not detect any significant association between the BRAF status of the 305 
tumors and patient outcome, neither when we analyzed all tumors, nor when we analyzed only the 306 
TCV. These findings are supported by other groups which were also not able to find such a 307 
relationship(Barbaro et al. 2014; Eloy et al. 2011; Ito et al. 2009; Koperek et al. 2012; Sancisi et al. 308 
2012). Epidemiologically, it is not surprising that the BRAF mutation does not predict ACO, since 309 
BRAF mutations can be found in about 40-50% of PTC, whereas less than 5% of these tumors have an 310 
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aggressive clinical course. Therefore, we believe that additional factors have to be present that account 311 
for the ACO in patients harboring this mutation.  312 
One of these potential additional factors could be TERT promoter mutations. They were 313 
recently discovered to be a novel mechanism of telomerase activation, which is known to be centrally 314 
involved in the tumorigenesis of various human cancer types including thyroid(Vinagre et al. 2013). 315 
From a diagnostic standpoint of view, it is worthwhile to mention that TERT promoter mutations were 316 
not detected in medullary thyroid carcinomas, nor in benign lesions or normal thyroid(Vinagre et al. 317 
2013). More important, recent studies including TCGA data reported TERT promoter mutations to 318 
play a role in aggressive thyroid cancers and in tumor progression from well differentiated to poorly 319 
and anaplastic thyroid carcinomas. The various studies found a frequency in PTC ranging from 8-25% 320 
and to being associated with an unfavorable prognosis(Cancer Genome Atlas Research 2014; Liu et al. 321 
2013a; Liu et al. 2013b; Melo, et al. 2014; Shimamura, et al. 2014; Vinagre et al. 2013). They occur 322 
significantly more often in TCV (30%) compared to conventional PTC or FVPTC (10%), and in 323 
poorly differentiated thyroid carcinomas (21-37%) compared to the differentiated subtypes (PTC or 324 
FTC: 12%) and have a high incidence in anaplastic thyroid carcinomas (13-46%)(Liu et al. 2013b; 325 
Vinagre et al. 2013). Although TERT promoter mutations significantly contribute to an ACO in PTC 326 
patients, many PTCs with an ACO including most TCV were TERT wild type. Thus, other molecular 327 
players being responsible for TC morphology and an ACO are yet to be discovered.  328 
 329 
Conclusions 330 
We show that presence of as few as 10% of TC within a PTC significantly affects patient 331 
prognosis. Therefore, these tumors should be classified accordingly and reported by the pathologist so 332 
the treating clinicians are aware that they are dealing with an aggressive neoplasm. The BRAF 333 
mutation did not affect patient outcome. Nevertheless, a mutation analysis for BRAF might be helpful 334 
in clinical management since a positive BRAF status may trigger the search for TC in order to predict 335 
patient outcome and new therapeutics inhibiting the mutated protein are now clinically available. 336 
TERT promoter mutations are too rare to serve as a surrogate marker for TC. However, they are a 337 
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novel tool to predict molecularly an adverse outcome in a subset of patients and an implementation 338 
into daily molecular diagnostics is worthwhile.  339 
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A: Papillary cancer; tall cell variant: tumor cells are at least thrice as height as their width and show an 
eosinophilic cytoplasm and elongated follicles (HE, 200x)  
B: Same tumor as A: Papillary cancer; tall cell variant: three times as height as width cells arranged in a 
“tram track” pattern with eosinophilic cytoplasm (HE, 400x)  
C: Papillary cancer; tall cell variant: papillary growth pattern with delicate branching of papillae (HE, 200x)  
D: Same tumor as C: Papillary cancer; tall cell variant: three times as height as width cells, growing in a 
classic papillary fashion (HE, 400x)  
E: Not all cells in these tumors are at least three times high as width. However, tumor cells growing in the 
“tram track” pattern should trigger a careful search for tall cells (HE, 200x)  
F: Same tumor as E: Tumor cells are cut tangential to their base (upper). Only cells can be assessed where 
the basal membrane is seen (lower). These tumor cells are classic tall cells, often with nuclear grooves and 
elongated follicles (HE, 400x)  
184x209mm (300 x 300 DPI)  
 
 
Page 18 of 26
p<0.001
A B
C D
p<0.001
p<0.001p<0.001
Page 19 of 26
p<0.095 p<0.272 p<0.001
A
D E
B
p<0.267 p<0.130 p<0.085
C
F
Page 20 of 26
Table 1: Clinicopathological 
data 
          
                total (n) ACO CG p-value 
      
age  
age <48 69 (55.2%) 32 (25.6%) 37 (29.6%) 
0.859 
      age ≥48 56 (44.8%) 25 (20%) 31 (24.8%) 
      
gender 
male 34 (27.2%) 20 (16%) 14 (11.2%) 
0.106 
      female 91 (72.8%) 37 (29.6%) 54 (43.8%) 
      
pT 
pT 1-2 55 (44%) 18 (14.4%) 37 (29.6%) 
0.012 
      pT 3-4 70 (56%) 39 (31.2%) 31 (24.8%) 
      
LN no metastasis 
104 
(83.2%) 38 (30.4%) 66 (52.8%) 0.001 
      metastasis 21 (16.8%) 19 (15.2%) 2 (1.6%) 
      
TC 
TC <10% 77 (61.6%) 21 (16.8%) 56 (44.8%) 
0.00001 
      TC ≥10% 48 (38.4%) 36 (28.8%) 12 (9.6%) 
      
BRAF total* 
wild type 49 (39.2%) 17 (13.6%) 32 (25.6%) 
0.066 
      mutated 76 (60.8%) 40 (32.0%) 36 (28.8%) 
      
TERT wild type 
102 
(92.7%) 45 (40.9%) 57 (51.8%) 0.002 
      mutated 8 (7.3%) 8 (7.3%) 0 (0%) 
      Chi Square test 
           Clinical and pathological characteritics between the adverse clinical outcome group (ACO) and the control group (CG) 
  * result of BRAF testing by pyrosequencing or by the VE1 antibody where no BRAF mutational testing by pyrosequencing was possible 
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Table 2: Clinicopathological data 
 
    total (n) TC <10% (n) TC ≥10% (n) p-value TC <50% (n) TC ≥50% (n) p-value 
age  
age <48 69 (55.2%) 44 (35.2%) 25  (20%) 
0.586 
62 (49.6%) 7 (5.6%) 
0.032 
age ≥48 56 (44.8%) 33  (26.4%) 23  (18.4%) 42 (33.6%) 14 (11.2%) 
gender 
male 34 (27.2%) 17 (13.6%) 17 (13.6%) 
0.147 
26 (20.8%) 8 (6.4%) 
0.282 
female 91 (72.8%) 60 (48%) 31 (24.8%) 78 (62.4%) 13 (10.4%) 
pT 
pT 1-2 55 (44%) 40 (32%) 15 (12%) 
0.027 
51 (40.8%) 4 (3.2%) 
0.015 
pT 3-4 70 (56%) 37 (29.6%) 33 (26.4%) 53 (42.4%) 17 (13.6%) 
LN 
no 
metastasis 
104 
(83.2%) 74 (59.2%) 30 (24%) 0.0001 90 (72%) 14 (11.2%) 0.049 
metastasis 21 (16.8%) 3 (2.4%) 18(14.4%) 14 (11.2%) 7 (5.6%) 
OS 
censored 
111 
(88.8%) 75 (60%) 36 (28.8%) 0.0001 97 (77.6%) 14 (11.2%) 0.002 
OS death 14 (11.2%) 2 (1.6%) 12 (9.6%) 7 (5.6%) 7 (5.6%) 
TSS 
censored 
118 
(94.4%) 77 (61.6%) 41 (32.8%) 0.001 102 (81.6%) 16 (12.8%) 0.001 
TSS death 7 (5.6%) 0 (0%) 7 (5.6%) 2 (1.6%) 5 (4%) 
RFS 
censored 
68  
(54.4%) 56 (44.8%) 12 (9.6%) 0.0001 66 (52.8%) 2 (1.6%) 0.0001 
RFS relapse 57 (45.6%) 21 (16.8%) 36 (28.8%) 38 (30.4%) 19 (15.2%) 
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Table 3: Tall cells, BRAF and TERT 
 
    total (n) TC <10% (n) TC ≥10% (n) p-value TC <50% (n) TC ≥50% (n) p-value 
BRAF pyro 
wild 
type 46 (39%) 37 (31.4%) 9 (7.6%) 0.001 41 (34.7%) 5 (4.2%) 0.143 
mutated 72 (61%) 35 (29.7%) 37 (31.4%) 56 (47.5%) 16 (13.6%) 
BRAF antibody 
wild 
type 62 (49.6%) 45 (36%) 17 (13.6%) 0.017 53 (42.4%) 9 (7.2%) 0.633 
mutated 63 (50.4%) 32 (25.6%) 31 (24.8%) 51 (40.8%) 12 (9.6%) 
BRAF total 
wild 
type 49 (39.2%) 39 (31.2%) 10 (8%) 0.001 44 (35.2%) 5 (4%) 0.088 
mutated 76 (60.8%) 38 (30.4%) 38 (30.4%) 60 (48%) 16 (12.8%) 
TERT 
wild 
type 102 (92.7%) 65 (59.1%) 37 (33.6%) 0.004 89 (80.9%) 13 (11.8%) 0.0003 
mutated 8 (7.3%) 1 (0.9%) 7 (6.4%) 2 (1.8%) 6 (5.5%) 
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Table and Figure Legends 1 
Figure 1:  A: Papillary cancer; tall cell variant: tumor cells are at least thrice as height as their 2 
width and show an eosinophilic cytoplasm and elongated follicles (HE, 200x)  3 
B: Same tumor as A: Papillary cancer; tall cell variant: three times as height as width 4 
cells arranged in a “tram track” pattern with eosinophilic cytoplasm (HE, 400x) 5 
C: Papillary cancer; tall cell variant: papillary growth pattern with delicate branching 6 
of papillae (HE, 200x) 7 
D: Same tumor as C: Papillary cancer; tall cell variant: three times as height as width 8 
cells, growing in a classic papillary fashion (HE, 400x) 9 
E: Not all cells in these tumors are at least three times high as width. However, tumor 10 
cells growing in the “tram track” pattern should trigger a careful search for tall cells (HE, 11 
200x) 12 
F: Same tumor as E: Tumor cells are cut tangential to their base (upper). Only cells 13 
can be assessed where the basal membrane is seen (lower). These tumor cells are classic tall 14 
cells, often with nuclear grooves and elongated follicles (HE, 400x) 15 
 16 
Figure 2:  A: Kaplan Meier, overall survival; tall cells <10% and >=10%; Log Rank p<0.001; 17 
TC <10%: Mean ± Std. error: 200.07 ± 7.37; 95%CI: 185.62 – 214.52; TC >=10%: Mean ± 18 
Std. error: 152.14 ± 14.90; 95%CI: 122.93 – 181.34. 19 
  B: Kaplan Meier, relapse free survival; tall cells <10% and >=10%; Log Rank 20 
p<0.001; TC <10%: Mean ± Std. error: 150.98 ± 10.9; 95%CI: 129.63 – 172.32; TC >=10%: 21 
Mean ± Std. error: 40.20 ± 7.0; 95%CI: 26.49 – 53.91. 22 
C: Kaplan Meier, overall survival; tall cells <10% vs. >=10% - <50%, Log Rank 23 
p<0.001 and tall cells >=10% - <50% vs. >=50%; Log Rank p<0.518;  24 
TC <10%: Mean ± Std. error: 200.07 ± 7.37; 95%CI: 185.62 – 214.52; TC >=10% - 25 
<50%: Mean ± Std. error: 162.48 ± 14.94; 95%CI: 133.20 – 191.76; TC >=50%: Mean ± Std. 26 
error: 138.85 ± 20.18; 95%CI: 99.30 – 178.40. 27 
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D: Kaplan Meier, relapse free survival; tall cells <10% vs. >=10% - <50%, Log Rank 28 
p<0.001; and tall cells >=10% - <50% vs. >=50%; Log Rank p<0.379;  29 
TC <10%: Mean ± Std. error: 150.98 ± 10.9; 95%CI: 129.63 – 172.32; TC >=10% - 30 
<50%: Mean ± Std. error: 50.32 ± 10.87; 95%CI: 29.01 – 71.63; TC >=50%: Mean ± Std. 31 
error: 32.43 ± 8.58; 95%CI: 15.62 – 49.24. 32 
 33 
Figure 3:  The influence of BRAF (A – C) and TERT promoter mutations (D – F) on overall 34 
survival, tumor specific survival or relapse free survival in patients with PTC; all Log Rank test 35 
 A; Kaplan Meier, overall survival, BRAF wt Mean ± Std. error: 191.75 ± 11.04; 95%CI: 36 
170.11 – 213.38; BRAF V600E: Mean ± Std. error: 175.60 ± 10.30; 95%CI: 155.40 – 195.79 37 
 B; Kaplan Meier, tumor specific survival, BRAF wt Mean ± Std. error: 210.22 ± 4.65; 95%CI: 38 
201.10 – 219.33; BRAF V600E: Mean ± Std. error: 187.34 ± 9.30; 95%CI: 169.11 – 205.58  39 
C; Kaplan Meier, relapse free survival, BRAF wt Mean ± Std. error: 121.822 ± 12.76; 95%CI: 40 
96.82 – 146.82; BRAF V600E: Mean ± Std. error: 96.99 ± 12.08; 95%CI: 73.31 – 120.67 41 
D; Kaplan Meier, overall survival, TERT promoter wt Mean ± Std. error: 196.64 ± 8.84; 42 
95%CI: 169.31 – 203.96; TERT promoter mutated: Mean ± Std. error: 107.18 ± 19.80; 95%CI: 68.37 – 43 
145.99 44 
E; Kaplan Meier, tumor specific survival, TERT promoter wt Mean ± Std. error: 200.60 ± 45 
6.39; 95%CI: 188.08 – 213.11; TERT promoter mutated: Mean ± Std. error: 127.63 ± 13.38; 95%CI: 46 
101.40 – 153.86 47 
F; Kaplan Meier, relapse free survival, TERT promoter wt Mean ± Std. error: 101.34 ± 9.09; 48 
95%CI: 83.52 – 119.16; TERT promoter mutated: Mean ± Std. error: 16.13 ± 6.15; 95%CI: 4.07 – 49 
28.18 50 
 51 
Figure suppl.1: ROC curves for tall cells in the different tumors. Results for the different survival  52 
endpoints are all significant. 53 
 54 
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Table 1: Clinical and pathological characteristics between the adverse clinical outcome group (ACO) 55 
and the control group (CG); (Chi-Square test). 56 
 57 
Table 2: Clinicopathological characteristics of the study population for PTC (Papillary thyroid 58 
carcinoma) with different cutoffs for the TCV (Tall cell variant of papillary thyroid carcinoma); TC = 59 
Tall cells, OS = overall survival, TSS = tumor specific survival, RFS = relapse free survival, (Chi-60 
Square test). 61 
 62 
Table 3: Tall cells, BRAF and TERT promoter mutation status of the study population for PTC 63 
(Papillary thyroid carcinoma) with different cutoffs for the TCV. 64 
BRAF pyro = BRAF V600E mutational status as detected by pyrosequencing; BRAF antibody = BRAF 65 
V600E mutational status as detected by the mutation specific VE1 antibody for BRAF V600E; BRAF 66 
total = BRAF V600E mutational status as detected by pyrosequencing when available and otherwise by 67 
the mutation specific VE1 antibody for BRAF V600E; (Chi-Square test).  68 
 69 
Table suppl.1: Percentage of TC areas in different tumors and number of patients with different 70 
survival events. 71 
 72 
Table suppl.2: Correlations and significances between different important clinicopathological data 73 
(Kendall’s tau_b). **Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at 74 
the 0.05 level (2-tailed). 75 
 76 
Table suppl.3: Detailed results of different multivariate analyses (Cox regression).  77 
 78 
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